Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, TD Cowen Analyst Says

Gilead Sciences (NASDAQ:GILD) had its price objective hoisted by stock analysts at TD Cowen from $115.00 to $125.00 in a research note issued on Thursday, MarketBeat.com reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s price objective points to a potential upside of 3.36% from the stock’s previous close.

A number of other equities analysts also recently commented on the company. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Cantor Fitzgerald boosted their price objective on Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Citigroup boosted their price objective on Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Wednesday, October 8th. Finally, BMO Capital Markets boosted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $122.61.

Gilead Sciences Stock Up 0.2%

Shares of GILD opened at $120.94 on Thursday. The firm has a market cap of $150.06 billion, a P/E ratio of 24.09, a price-to-earnings-growth ratio of 0.83 and a beta of 0.34. Gilead Sciences has a 12-month low of $86.08 and a 12-month high of $124.61. The company’s 50-day moving average price is $115.47 and its 200 day moving average price is $111.01. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $354,240.00. Following the completion of the transaction, the insider owned 110,193 shares in the company, valued at approximately $13,011,589.44. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares of the company’s stock, valued at $18,545,054.40. The trade was a 1.57% decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,500 shares of company stock worth $8,281,540 over the last 90 days. 0.27% of the stock is currently owned by insiders.

Institutional Trading of Gilead Sciences

Several large investors have recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences during the first quarter valued at $25,000. Activest Wealth Management boosted its stake in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. GoalVest Advisory LLC boosted its stake in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences during the third quarter valued at $26,000. Finally, Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences during the second quarter valued at $27,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.